Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glasdegib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glasdegib SCHEMBL24503991 | 1.00 | EPHX1 (0.45) | EPHX1NPC1RAB9AUSP30POLB | |
| Glasdegib SCHEMBL22104131 | 1.00 | EPHX1 (0.45) | EPHX1NPC1RAB9AUSP30POLB | |
| Glasdegib SCHEMBL27100349 | 1.00 | EPHX1 (0.45) | EPHX1NPC1RAB9AUSP30POLB | |
| Glasdegib SCHEMBL18184932 | 1.00 | EPHX1 (0.45) | EPHX1NPC1RAB9AUSP30POLB | |
| Glasdegib SCHEMBL29359708 | 1.00 | EPHX1 (0.45) | EPHX1NPC1RAB9AUSP30POLB | |
| Glasdegib SCHEMBL29362720 | 0.99 | EPHX1 (0.44) | EPHX1NPC1RAB9AUSP30POLB | |
| Glasdegib SCHEMBL2068016 | 0.99 | EPHX1 (0.44) | EPHX1NPC1RAB9AUSP30POLB | |
| Glasdegib SCHEMBL29359798 | 0.95 | USP30 (0.41) | EPHX1NPC1RAB9AUSP30POLB | |
| Glasdegib SCHEMBL18171549 | 0.95 | USP30 (0.41) | EPHX1NPC1RAB9AUSP30POLB | |
| Glasdegib SCHEMBL18171548 | 0.95 | USP30 (0.41) | EPHX1NPC1RAB9AUSP30POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891373-B2 | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate | PFIZER INC. (US) | 2024-02-06 | — | — | US | claimed |
| EP-3666768-B1 | PREPARATION PROCESS OF A CRYSTALLINE FORM OF 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA MALEATE; A CRYSTALLINE FORM OF 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA IMIDAZOLE COMPLEX (1:1) | PFIZER (US) | 2022-06-15 | — | — | EP | claimed |
| US-20220024894-A1 | CRYSTALLINE FORMS OF 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA MALEATE | PFIZER INC. (US) | 2022-01-27 | — | — | US | claimed |
| EP-2170860-B9 | BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2017-02-22 | — | — | EP | claimed |
| EP-2170860-B1 | BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2016-11-02 | — | — | EP | claimed |
| WO-2016042114-A1 | CXCL14 AS A BIOMARKER OF HEDGEHOG PATHWAY ACTIVITY FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-03-24 | — | — | WO | claimed |
| WO-2015073524-A1 | NOVEL METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE | DREXEL UNIVERSITY (US) | 2015-05-21 | — | — | WO | claimed |
| US-8148401-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2012-04-03 | — | — | US | claimed |
| EP-2170860-A2 | BENZIMIDAZOLE DERIVATIVES | Pfizer Inc. (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2009004427-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2009-01-08 | — | — | WO | claimed |
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2009-01-01 | — | — | US | claimed |
| CN-118021814-A | Combination therapy with EHMT2 inhibitors | EPIZYME股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4126237-C0 | DIMALEATE FORM OF 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA | LEK PHARMACEUTICALS (SI) | 2024-04-10 | — | — | EP | disclosed |
| EP-4126237-B1 | DIMALEATE FORM OF 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA | LEK PHARMACEUTICALS (SI) | 2024-04-10 | — | — | EP | disclosed |
| EP-4126237-B1 | DIMALEATE FORM OF 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA | LEK PHARMACEUTICALS (SI) | 2024-04-10 | — | — | EP | disclosed |
| WO-2009004427-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009004427-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024894-A1 | CRYSTALLINE FORMS OF 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA MALEATE | RCC1, UACA, LYAR | EPHX1 4818/4885NPC1 649/4885RAB9A 3945/4885 |
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | BOD1L1, H1-3, BRIX1 | EPHX1 4079/4885NPC1 2444/4885RAB9A 1426/4885 |
| US-11891373-B2 | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate | RCC1, UACA, LYAR | EPHX1 4818/4885NPC1 649/4885RAB9A 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.